EGFR and lung adenocarcinoma: In another study of 111 patients with EGFR‐mutant lung adenocarcinoma, the acquired T790M‐mutant group (n = 58, 52.3%) had a significantly longer overall survival (p = 0.010) compared to patients without T790M mutation.21